Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Study of the Safety and Efficacy of Botox in Bruxism

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態
スポンサー
Baylor College of Medicine
共同編集者
Allergan

キーワード

概要

The purpose of this study is to determine whether botulinum toxin helps patients with bruxism.

説明

Bruxism represents involuntary movements of the jaw muscles, resulting in tooth grinding and clenching. Generally it occurs during sleep, but occasionally can be present during the day, so called awake bruxism. Bruxism is a common condition, affecting approximately 8% of all people. It is not known what causes bruxism but it may result in tooth damage, jaw pain, headaches, poor quality sleep and may bother your partner's sleep at night due to the tooth grinding noise. There is no generally accepted treatment for bruxism. Mouth guards and several medications have been tried, but they generally did not work or caused side effects.

Botulinum toxin "Botox" is a natural toxin, which weakens the muscles when injected in very small amounts. It is currently approved and used for the treatment of various conditions involving abnormal muscle spasms, such as neck twisting (torticollis), twitching of the face (hemifacial spasm) or eyes (blepharospasm), headaches, muscles stiffness following strokes, and it has also been used cosmetically for wrinkle removal.

Since bruxism is caused by involuntary spasms of the jaw muscles, botulinum toxin has been tried, initial results showing that it is safe and effective. The injections generally take one week to start working and 2 weeks for a full effect, which lasts on average 12-16 weeks, and slowly wear off. The injections are generally repeated every 3-4 months.

日付

最終確認済み: 08/31/2010
最初に提出された: 05/20/2009
提出された推定登録数: 05/21/2009
最初の投稿: 05/24/2009
最終更新が送信されました: 06/22/2011
最終更新日: 06/26/2011
実際の研究開始日: 03/31/2009
一次完了予定日: 11/30/2011
研究完了予定日: 06/30/2012

状態または病気

Bruxism

介入/治療

Drug: Botulinum toxin type A

段階

段階 4

アームグループ

介入/治療
Placebo Comparator: Placebo
Placebo arm
Active Comparator: botulinum toxin type A
Active arm

適格基準

研究の対象となる年齢 18 Years に 18 Years
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

- 1. Patients between the ages of 18 and 80 years old with a diagnosis of bruxism, based on the standard criteria.

- 2. If the subject is a female of childbearing age, she must have had a hysterectomy, tubal ligation, or otherwise be incapable of pregnancy, or have practiced a method of contraception (hormonal contraceptives, spermicidal barrier, intrauterine device, partner sterility) at least one month prior to study entry. Any female of childbearing age will have a urine pregnancy test one week prior to the treatment (visit 2).

- 3. Ability of the patient or guardian to sign and understand informed consent.

- 4. Ability to follow and comply with study directions.

Exclusion Criteria:

- 1. Coexistence of active psychosis, other active psychiatric disease or cognitive impairment.

- 2. Coexistence of serious co-morbid conditions.

- 3. Exposure to any botulinum toxin preparation within the past 6 months.

- 4. Participation in another experimental therapeutic protocol within 30 days.

- 5. Any medical condition in which the administration of botulinum toxin is contraindicated, including myasthenia gravis, amyotrophic lateral sclerosis or other neuromuscular diseases.

- 6. History of dysphagia.

- 7. History of botulism.

- 8. A condition or situation in which the investigators view will confound the ability of the subject to participate in the study.

- 9. Patients or guardian who are unable to understand and sign informed consent.

- 10. Pregnancy

- 11. Patients who do not meet inclusion criteria.

- 12. Patients in whom it is felt that a major portion of overall sleep morbidity is not related to bruxism.

結果

主な結果の測定

1. Age and maximum masseter voluntary contractions (MVC) [baseline for the treatment versus placebo groups]

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge